We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 Jul 2025

Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. More...

In conjunction with their recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give health professionals globally access to tools that will assist in the detection of cancer.

Lunit and Microsoft will collaborate to develop a service that allows fine-tuning of AI models using site-specific clinical data from each customer. This approach helps mitigate cross-site model performance variability—one of the key challenges in deploying AI in real-world clinical environments—and ensures more reliable, tailored outcomes in diverse clinical settings. Moving beyond point solutions, Lunit will leverage Microsoft's agentic AI frameworks—designed to support intelligent task automation—to develop end-to-end workflow automation tools. These solutions aim to simplify clinical decision-making and enhance operational efficiency across the care continuum.

This collaboration underscores Lunit's long-term vision to move beyond standalone AI tools toward building integrated solutions that align with real-world clinical practice. By joining forces with Microsoft, Lunit is poised to deliver scalable technologies that not only streamline radiology workflows but also drive measurable improvements in diagnostic consistency and patient care across diverse healthcare settings. This collaboration marks a significant milestone in Lunit's mission to expand access to AI tools, particularly in the U.S. market, by leveraging Microsoft Azure's global cloud infrastructure and deep expertise in healthcare-focused AI technologies.

"For AI to truly make an impact in healthcare, it must be accessible, scalable, and seamlessly integrated into clinical practice," said Brandon Suh, CEO of Lunit. "Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the U.S. and beyond. This collaboration brings us one step closer to delivering high-quality, consistent care through AI—at scale."

"With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations," said Naveen Valluri, General Manager, Health and Life Sciences Data and AI at Microsoft. "By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of intelligent, integrated solutions for radiology and beyond."

Related Links:
Lunit
Microsoft


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology System
Medonic M16C
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Illustration of a cross-section of a blood vessel with red blood cells, white blood cells, and fragments of DNA (Photo Courtesy of UC San Diego/Adobe Firefly)

Microbial DNA Signature in Blood Plasma Differentiates Two Liver Cancer Types

Determining whether a cancerous tumor originated in a given location or spread from another organ is critical for guiding diagnosis and treatment decisions. When the primary tumor site cannot be identified,... Read more

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.